Japan plans to revise its guidelines on the drone delivery of medicines later this month, which would mark the first revision since they were established two years ago. Service providers are closely watching how they will be revised, with calls…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Novartis Japan Sees 2023 OK for 1st siRNA Drug for Hyperlipidemia, 7 Approvals to Drive Growth
March 27, 2023
-
ORGANIZATION Japan Umbrella Trade Organ to Beef Up Functions for Lobbying Activity
March 24, 2023
-
REGULATORY Generic Dispensing Tops 82%; 57% of Pharmacies Not Active on Biosimilars: Poll
March 23, 2023
-
REGULATORY MHLW Council Discusses Root Causes of Drug Supply Disruptions, Yakkasa Issues
March 22, 2023
-
REGULATORY Expert Panel Talks over Yakkasa, Revamp of Price Revision Method; Fixed Margin, Claw-Back Mooted
March 20, 2023
-
BUSINESS CSL R&D Head Touts Cost-Effectiveness of Hemophilia Gene Therapy Hemgenix
March 17, 2023
-
BUSINESS Illumina Eyes Japan Launch of Comprehensive Genomic Profiling Test This Year
March 16, 2023
-
BUSINESS Teijin Pharma Plans Pivot to Rare Diseases as Generics Eat into Feburic Sales
March 15, 2023
-
BUSINESS Eisai’s Leqembi Wins Coverage from US Veteran’s Body
March 15, 2023
-
BUSINESS Bayer Setting Out to Cut Up to 480 Jobs as Xarelto Patent Cliff Looms: Employee
March 14, 2023
-
BUSINESS AstraZeneca Looks to 1st IO/ADC Launch as Leader in the Race: Oncology Head
March 13, 2023
-
ORGANIZATION PhRMA Unveils Proposal for FY2024 Reform, Says This Year Is “Turning Point” to Improve Access
March 10, 2023
-
REGULATORY Xocova Priced at 51,851 Yen per Course with Peak Sales Put at 19.2 Billion Yen
March 9, 2023
-
REGULATORY Expert Narukawa Backs JPMA Pitch on Value-Based Pricing, but Disputes Blanket Price Maintenance for Patented Meds
March 8, 2023
-
BUSINESS Azilva, Abraxane, and More Major Meds Get Add-On PMPs under Ad-Hoc Rule in FY2023: Poll
March 7, 2023
-
BUSINESS Drug Makers Wary of Rush Demand Tied to Unprofitability Re-Pricing, Some Curb Orders
March 7, 2023
-
BUSINESS 2023 Price Cut for Top-Tier, 2nd-Tier Firms at 1-4%, Tsumura Only Original Drug Maker to See Net Rise: Jiho Poll
March 6, 2023
-
REGULATORY MHLW Unveils New List Prices for FY2023 Revision, Ad-Hoc PMP Raise for 143 Products
March 3, 2023
-
BUSINESS Nichi-Iko to Discontinue 221 Additional Products, Generic Peers Looking into Impact
March 2, 2023
-
BUSINESS Nichi-Iko Exits North American Market, Biosimilar Biz with Sagent Sell-Off
March 1, 2023
ページ
The healthcare supply chain in Japan, as in all major markets, consists of biopharmaceutical manufacturers selling to wholesalers who in turn sell to hospitals, clinics, and pharmacies, where the drugs are finally dispensed to patients. Each party ideally contributes value…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…